considered nontoxic, have been associated with toxicity reports from time to time. Thus, the agency is also interested in receiving data or comments concerning the need for a general warning statement or other actions applicable to parenteral drug products containing any substance that could be considered a preservative intended for newborn infants, other special patient populations, or for all patients.

In addition to submitting data, comments, or suggestions regarding the issues discussed above or related concerns, the agency is interested in receiving data concerning the economic effects of any of the actions discussed above.

Interested persons may, on or before July 15, 1985, submit to the Dockets Management Branch (address above) written comments concerning this notice of intent. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets at the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

Dated: May 3, 1985.

Frank E. Young,

Commissioner of Food and Drugs.

[FR Doc. 85-11662 Filed 5-14-85; 8:45 am]

BILLING CODE 4160-01-M

21 CFR Part 334

[Docket No. 78N-036L]

Laxative Drug Products for Over-the-Counter Human Use; Tentative Final Monograph

AGENCY: Food and Drug Administration.

ACTION: Notice of proposed rulemaking; extension of comment period.

SUMMARY: The Food and Drug Administration (FDA) is extending to June 14, 1985, the comment period for the notice of proposed rulemaking to establish conditions for the safety, effectiveness, and labeling of over-the-counter (OTC) laxative drug products. This action is being taken in response to a request to allow more time for interested persons to address adequately several important issues and to consult experts so that more informed comments may be submitted to FDA.

DATE: Written comments by June 14, 1985.

ADDRESS: Written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: William E. Gilbertson, Center for Drugs and Biologics (HFN-210), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-4960.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of January 15, 1985 (50 FR 2124), FDA issued a notice of proposed rulemaking to establish conditions for the safety, effectiveness, and labeling of OTC laxative drug products. The notice of proposed rulemaking is part of the ongoing review of OTC drug products conducted by the agency. Interested persons were given until May 15, 1985, to comment on the notice of proposed rulemaking.

In response to the proposal, one comment requested a 30-day extension of the comment period to study the issues adequately relating to bulk-forming fiber laxatives and to confer with outside consultants.

FDA has carefully considered the request. The agency believes that information described by the request may be of assistance in establishing the final rule for OTC laxative drug products and is in the public interest. Therefore, the agency considers a general extension of the comment period for 30 days to be appropriate. Accordingly, the comment period for submissions by any interested person is extended to June 14, 1985. Comments may be seen in the Dockets Management Branch, Food and Drug Administration, at the address noted above, between 9 a.m. and 4 p.m., Monday through Friday.

Dated May 9, 1985.

John R. Wessel,

Acting Associate Commissioner for Regulatory Affairs.

[FR Doc. 85-11651 Filed 5-10-85; 2:32 pm]

BILLING CODE 4160-01-M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Secretary

24 CFR Parts 25, 203, 205, 213, 221, and 244

[Docket No. R-85-1226; FR-1954]

Use of Commitment Correspondents in Connection With FHA Mortgage Insurance

Correction

In FR Doc. 85-10734 beginning on page 18680 in the issue of Thursday, May 2, 1985, make the following corrections:

1. On page 18682, in the third column, under **PART 25—MORTGAGEE REVIEW BOARD**, and above the **Authority** citation, insert: "1. The authority citation for 24 CFR Part 25 is revised to read as set forth below and any authority citation following any section in Part 25 is removed:".

2. On page 18685, in the first column, the authority citation for Part 203 should have followed amendatory instruction 9.

3. On page 18687, in the first column, the authority citation for Part 205 should have followed amendatory instruction 15.

4. On page 18687, the authority citation for Part 213 should have followed amendatory instruction 19 in the first column.

5. On page 18687, in the second column, the authority citation for Part 221 should have followed amendatory instruction 22.

6. On page 18688, in the first column, amendatory instruction "30" under Part 244, should read "34".

BILLING CODE 1505-01-M

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 180

[OPP-300128; FRL-2835-7]

Alpha-(p-Nonylphenyl)-Omega-Hydroxypoly(Oxyethylene) Mixture of Dihydrogen Phosphate and Monohydrogen Phosphate Esters and the Corresponding Salts; Exemption

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: This document proposes to expand the exemption from the requirement of a tolerance for *alpha*-(*p*-nonylphenyl)-omega-hydroxypoly(oxyethylene) mixture of dihydrogen phosphate and monohydrogen phosphate esters and the corresponding ammonium, calcium, magnesium, monoethanolamine, potassium, sodium, and zinc salts of the phosphate esters when used as inert ingredient surfactants, related adjuvants of surfactants in pesticide formulations applied to growing crops or to raw agricultural commodities after harvest. This proposed regulation was requested by DeSoto, Inc.

DATE: Written comments, identified by the document control number [OPP-300128], must be received on or before June 14, 1985.